Loading...
Market
What will be the real-world response rate of zanidatamab-hrii by the end of 2025?
2
Resolution / Starting Odds
Less than 40% • 25%
40% to 50% • 25%
51% to 60% • 25%
More than 60% • 25%
Results published in medical journals or presented at oncology conferences
Story
FDA Approves Jazz's Zanidatamab for HER2+ Biliary Cancer with 52% Response Rate
Nov 21, 2024, 12:36 AM
The U.S. Food and Drug Administration (FDA) has approved a new drug, zanidatamab-hrii (Ziihera), developed by Jazz Pharmaceuticals, for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC). This approval marks a significant advancement in the treatment of this specific cancer type, with the drug showing a 52% response rate and a median duration of response of 14.9 months.
View original story
Similar markets
Above 55% • 25%
50-55% • 25%
45-50% • 25%
Below 45% • 25%
Less than 40% • 25%
40% to 49% • 25%
50% to 59% • 25%
60% or more • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Less than 50% • 25%
50% to 74% • 25%
75% to 80% • 25%
More than 80% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Less than 50% • 25%
50% - 60% • 25%
60% - 70% • 25%
More than 70% • 25%
Significant Improvement • 25%
Moderate Improvement • 25%
No Change • 25%
Worse Outcomes • 25%
Complete Response (CR) • 25%
Partial Response (PR) • 25%
Stable Disease (SD) • 25%
Progressive Disease (PD) • 25%
Less than 30% • 25%
30% to 49% • 25%
50% to 69% • 25%
70% or higher • 25%
PFS < 6 months • 25%
PFS 6-8 months • 25%
PFS 8-10 months • 25%
PFS > 10 months • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
Greater than 40% • 25%